ClinicalTrials.gg
CompletedNCT03259620Updated Sep 14, 2023Results posted

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

A Phase 3 interventional study of CLS006 and CLS006 Vehicle in Cutaneous Common Warts, sponsored by Maruho Co., Ltd.. Completed at 35 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Maruho Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
491
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.

Enrollment
3rd of 58
491 · median 80
Started
2017
with 3 others
Phase 3
11 of 59
2 open now
Registered
35th of 59
by date
Lead sponsor
2 of 59
Maruho Co., Ltd.

Among the 59 studies in Warts with a site in United States, this one is the 3rd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 35th registered.

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

Browse Warts studies →

Open to participants now

7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Warts with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).

03

Conditions studied

  • Cutaneous Common Warts

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk

    • Each wart must measure 3 to 10 mm in their longest dimension (diameter) on the epidermal plane of the skin at the baseline visit,
    • Each wart must be present for at least 4 weeks at the baseline visit,
    • Plantar, facial, subungual, and other warts (e.g., flat, genital) are excluded from treatment (i.e., these wart types are excluded from treatment, however the subject is not excluded).
  • Male or female subjects 2 years of age or older
  • Females of who are using a highly effective form of or females of non-childbearing potential
  • Negative in-office urine pregnancy test at Screening and Baseline
  • Subjects free of any dermatologic disorder in the treatment area
  • Subjects free of any clinically significant systemic condition which will interfere with the study assessments or increase the risk of AEs
  • Subjects willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows:

    • Salicylic acid, cantharidin, sinecatechins (VeregenTM), simple occlusion (e.g., duct tape), and/or any other over-the-counter wart-removing products in the treatment area within 4 weeks of the Baseline Visit.
    • Cryotherapy (e.g., treatment with liquid nitrogen), carbon dioxide, electrodessication, laser, surgery, or other forms of mechanical destruction (e.g., emery boards, clippers, debriders, etc.) in the treatment area within 8 weeks of the Baseline Visit.
    • Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil, bleomycin, podophyllin or any other wart immunotherapy or treatment (e.g., Candida antigen) designed to stimulate immune response within 12 weeks of the Baseline Visit.
  • Female subjects who are pregnant, nursing/breastfeeding, or plan to become pregnant within the study period including the follow-up period.
  • Subjects who are .
  • Subjects who have taken, within 30 days prior to the Baseline visit, or require treatment with systemic immunosuppressive or immunomodulatory medication (including oral or parenteral ) during the course of the study.
  • Subjects who require ongoing treatment with oral or injectable furosemide.
  • Subjects who have used an drug/device within 30 days of the Baseline visit
  • Subjects with known sensitivities to any of the investigational product ingredients including furosemide (or other sulfonamides).
  • Subjects with /significant abnormal laboratory results, vital signs, , and/or physical findings at Screening and/or Baseline
  • Subjects with a chronic medical condition or clinically significant abnormal physical or laboratory finding(s) that may require the use of a prohibited medication/treatment.
  • Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol or drug abuse within the past year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
491 participants (actual)

Study arms

  • Experimental
    CLS006

    Furosemide Topical Gel, 0.125%

    Drug: CLS006

  • Experimental
    CLS006 Vehicle

    Vehicle Topical Gel

    Drug: CLS006 Vehicle

Interventions

  • DrugCLS006

    Furosemide Topical Gel

  • DrugCLS006 Vehicle

    Vehicle Topical Gel

06

What researchers measure

Primary outcomes

  1. The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation

    Time frame: Week 18

Secondary outcomes

  1. The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject

    Time frame: Week 18

  2. Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12

    Time frame: Week 12

  3. The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 12

    Time frame: Week 12

  4. Change From Baseline in Wart Size for Each Subject

    Time frame: Week 18

07

Results

Posted Sep 14, 2023

Participant flow

Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk

Participant flow — Overall Study
MilestoneCLS006CLS006 Vehicle
Started245246
Subjects who had 1 wart112118
Subjects who had 2 warts4840
Subjects who had 3 warts2531
Subjects who had 4 warts1318
Subjects who had 5 warts2020
Subjects who had 6 warts2719
Completed226217
Not completed1929

Outcome measures

PrimaryThe Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation
Time frame:
Week 18
Reported as:
Count of participants · Participants
The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation
ParticipantsCLS006CLS006 Vehicle
Achieved complete clearance of all treated warts3527
Not achieved complete clearance of all treated warts191190
Statistical analysis
  • CLS006 · Cochran-Mantel-Haenszel · p = 0.2587
SecondaryThe Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject
Time frame:
Week 18
Reported as:
Mean · Ratio of Cleared Warts
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject
Ratio of Cleared WartsCLS006CLS006 Vehicle
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject0.210 ± 0.37710.191 ± 0.3500
SecondaryDifference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12
Time frame:
Week 12
Reported as:
Count of participants · Participants
Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12
ParticipantsCLS006CLS006 Vehicle
Complete clearance of all treated warts2119
Not complete clearance of all treated warts205198
SecondaryThe Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 12
Time frame:
Week 12
Reported as:
Mean · ratio of cleared warts
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 12
ratio of cleared wartsCLS006CLS006 Vehicle
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject at Week 120.135 ± 0.31120.127 ± 0.3020
SecondaryChange From Baseline in Wart Size for Each Subject
Time frame:
Week 18
Reported as:
Mean · mm
Change From Baseline in Wart Size for Each Subject
mmCLS006CLS006 Vehicle
Change From Baseline in Wart Size for Each Subject-3.5 ± 7.10-3.1 ± 6.84

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CLS0061/245 (0.4%)3/245 (1.2%)23/245 (9.4%)
CLS006 Vehicle1/246 (0.4%)3/246 (1.2%)14/246 (5.7%)
Most frequent serious events
Most frequent serious events
EventCLS006CLS006 Vehicle
Abdominal painGastrointestinal disorders1/2450/246
CardiomyopathyCardiac disorders1/2450/246
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2450/246
Bacterial colitisInfections and infestations0/2451/246
Gastrointestinal haemorrhageGastrointestinal disorders0/2451/246
Multiple sclerosisNervous system disorders0/2451/246
Most frequent other events
Most frequent other events
EventCLS006CLS006 Vehicle
NauseaGastrointestinal disorders5/2450/246
Upper respiratory tract infectionInfections and infestations5/2454/246
NasopharyngitisInfections and infestations4/2453/246
InfluenzaInfections and infestations3/2452/246
Pharyngitis streptococcalInfections and infestations3/2452/246
SinusitisInfections and infestations3/2453/246

Baseline characteristics

Age, Continuous
Age, Continuous(years)CLS006CLS006 VehicleTotal
Mean32.1 ± 18.8030.2 ± 17.2631.1 ± 18.05
Age, Customized
Age, Customized(Participants)CLS006CLS006 VehicleTotal
>=2 to <12394180
>=12 to <18404080
>=18 to <65150157307
>=6516824
Sex: Female, Male
Sex: Female, Male(Participants)CLS006CLS006 VehicleTotal
Female138129267
Male107117224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CLS006CLS006 VehicleTotal
Hispanic or Latino4769116
Not Hispanic or Latino198177375
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CLS006CLS006 VehicleTotal
American Indian or Alaska Native303
Asian8917
Native Hawaiian or Other Pacific Islander022
Black or African American51116
White219211430
More than one race000
Unknown or Not Reported101323
08

Study locations

35 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • West Dermatology Research Center
    San Diego, California 92121, United States
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • Colorado Medical Research Center, Inc.
    Denver, Colorado 80210, United States
  • Skin Care Research, Inc.
    Boca Raton, Florida 33486, United States
  • Dermatology Associates & Research
    Coral Gables, Florida 33134, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • International Clinical Research - US, LLC
    Sanford, Florida 32771, United States
  • Marietta Dermatology Clinical Research, Inc.
    Marietta, Georgia 30060, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • DS Research
    New Albany, Indiana 47150, United States
  • Center for Pharmaceutical Research, LLC
    Kansas City, Missouri 64114, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • The Dermatology Group, P.C.
    Verona, New Jersey 07044, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Skin Specialty Dermatology
    New York, New York 10155, United States
  • Darst Dermatology
    Charlotte, North Carolina 28277, United States
  • Dermatology Specialists of Charlotte
    Charlotte, North Carolina 28277, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Oregon Dermatology And Research Center
    Portland, Oregon 97210, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • PEAK Research, LLC
    Upper Saint Clair, Pennsylvania 15241, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Palmetto Clinical Trial Services, LLC
    Fountain Inn, South Carolina 29644, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Austin Institute for Clinical Research, Inc
    Pflugerville, Texas 78660, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Aug 2018, 9 months.

Results were first posted in Sep 2023, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 23, 2017
StartActual
Oct 30, 2017
Primary completionActual
Aug 22, 2018
CompletionActual
Nov 7, 2018
Results first posted
Sep 14, 2023
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03259620
Lead sponsor
Maruho Co., Ltd.
Responsible party
Sponsor
First posted
Aug 23, 2017
Start date
Oct 30, 2017
Primary completion
Aug 22, 2018
Completion
Nov 7, 2018
Results posted
Sep 14, 2023
Last update
Sep 14, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion